Erasca, Inc.
ERAS
Clasificación en acciones
#3372
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Precio por acción
$14.51
Última sincronización: 2026-10-21
Capitalización bursátil
$5.08B
Cambio (1 día)
-0.75%
Cambio (1 año)
539.21%
País
US
Comercio Erasca, Inc. (ERAS)
Categoría
Healthcare
Historial del precio de la acción de Erasca, Inc. (ERAS)
Precio más alto de cierre: $14.66 el 2026-10-01
Precio más bajo de cierre: $19.40 el 2021-07-01
Precio más bajo de cierre: $19.40 el 2021-07-01
Historial del precio de la acción de Erasca, Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 260.18% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
